News
2h
Stockhead on MSNRecce secures full entitlement shortfall to complete $15.8m raise for phase III clinical trialsRecce receives firm commitments to place the full shortfall from its entitlement offer raising a total of $15.8 million to ..
5h
Stockhead on MSNLeeuwin Metals zips ahead with drilling for gold extensions at MardaLeeuwin Metals has started phase 2 drilling at its Marda gold project to follow-up on high-grade gold intersected in the ...
It wasn't the sharpest practice for the Vikings' quarterback, though nothing matters too much this time of year.
Kura Oncology and Kyowa Kirin have shared details of the phase 2 win for their oral leukemia treatment ziftomenib as the FDA ...
Declan Rice has been named in the Champions League Team of the Season for 2024/25, after Arsenal’s run to the semi-finals of ...
Kymera Therapeutics reported positive results from its phase 1 healthy volunteer study using KT-621. Click here to find out ...
Dirk Arnold, MD, PhD, medical director, Asklepios Tumour Biology Centre, discusses a phase 3 clinical trial investigating amivantamab in metastatic colorectal cancer.
Half of the moon will be illuminated as it reaches its first quarter phase on Monday, June 2. The first quarter phase marks ...
Dr. Alan Bryce presented the preliminary results from a phase II trial of PT-112 monotherapy in late-line metastatic castration-resistant prostate cancer (mCRPC). Late-line mCRPC patients have poor ...
NEW YORK – Arrowhead Pharmaceuticals on Monday said it has treated the first patients with ARO-ALK7, an RNAi therapeutic that the company is developing for obesity, within a first-in-human Phase I/IIa ...
The PSA progression free survival in Arm A was 2.6 months versus 2.5 months in Arm B, and radiologic progression free survival was 2.1 months and 1.9 months in arm A and B, respectively. The median ...
Rusfertide (Protagonist Therapeutics/Takeda Pharmaceuticals) — administered as a once-weekly subcutaneous injection — also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results